first-line triplet in braf mcrc
Published 5 years ago • 115 plays • Length 3:25Download video MP4
Download video MP3
Similar videos
-
6:01
beacon trial: triplet therapy in braf v600e–mutated mcrc
-
6:06
colorectal cancer debate: first line braf v600e - targeted triplet
-
7:02
triplet regimens in braf-mutant metastatic crc
-
4:23
sequencing strategies in braf-mutated mcrc
-
1:00
dr. kopetz discusses triplet therapy for braf-mutant crc
-
1:32
dr. flaherty on the rationale to explore triplet therapy in braf v600e-mutant melanoma
-
2:18
prognosticating braf-mutant mcrc
-
4:51
colorectal cancer debate: first line braf v600e - folfoxiri/bev
-
6:22
erbitux for colon cancer
-
5:19
targeting braf v600e in metastatic colorectal cancer: where are we today?
-
20:35
01 multistep tumor formation
-
1:24
fire-4.5: folfoxiri plus either bevacizumab or cetuximab as 1l treatment of braf v600e-mutant mcrc
-
2:07
triplet regimen improves responses in braf v600e metastatic crc
-
2:24
real-world management of patients with braf-v600e mcrc
-
1:06
dr. cercek on targeted strategies in braf-mutant mcrc
-
1:09
dr. kopetz on updated data from beacon crc study in braf v600e–mutant crc
-
1:11
dr. kopetz on the rationale for the beacon crc study in braf v600e-mutant mcrc
-
9:20
initiating therapy for mcrc
-
0:54
dr. kopetz on safety data from beacon crc trial in braf v600e-mutant mcrc
-
3:42
evidence in braf-mutant crc tumors
-
8:16
beacon crc: first-line bevacizumab in colorectal cancer treatment
-
8:16
encorafenib & binimetinib cetuximab for untreated braf v600e-mutant metastatic colorectal cancer